Randy,
I'm not sure if the had a spa, and I actually doubt it. eMerck did run this trial through it's EMD subsidary which is U.S. based.
I wouldn't think they needed a special protocol because there's nothing special about the trial. I completely expect that BMY and IMCL are going to "package" all the data so that Erby would end up with the widest label possible in every line.
They were approved on the Bond trial, they have the 1100 patient MABEL trial to back it up, then they have the Canadian 3rd line OS trial, the 2nd line EPIC trial and now the CRYSTAL 1st line trial. They also have the OPUS trial which is a smaller (400pts) 1st line trial with folfox fully enrolled.
Guys, one thing you have to remember is that the effects of this trial go wide and far. Onc's now would feel comfortable enrolling patients in numerous trials.
As far as panitumumab is concerned, besides pacce they are so far behind the 8 ball and they're getting farther away. PR will only carry the day for so long Amgen and Genentech have to get serious.
News 
Market Data 
Discover 
AI
